Great turnout at the Founders Corner and excellent presentation from the Orphagen Pharmaceuticals team – Scott Thacher, Haiyan Tao, Paul Crowe. Thank you to the mentors who carved out time this afternoon to provide insightful feedback on strategy and positioning.
Orphagen is a pioneer in the screening, discovery and development of ligands that modulate orphan or unexplored members of the nuclear receptor family. They have proprietary small molecule leads and candidates for novel drug targets with potential applications in inflammatory disease and oncology.
